Pazopanib
- Generic Name
- Pazopanib
- Brand Names
- Votrient
- Drug Type
- Small Molecule
- Chemical Formula
- C21H23N7O2S
- CAS Number
- 444731-52-6
- Unique Ingredient Identifier
- 7RN5DR86CK
- Background
Pazopanib is a small molecule inhibitor of multiple protein tyrosine kinases with potential antineoplastic activity. It is developed by GlaxoSmithKline and was FDA approved on October 19, 2009.
- Indication
Treatment of advanced renal cell cancer and advanced soft tissue sarcoma (in patients previously treated with chemotherapy)
- Associated Conditions
- Advanced Renal Cell Carcinoma, Advanced Soft Tissue Sarcoma, Advanced Thyroid cancer
- Associated Therapies
- -
A Study to Investigate Efficacy & Safety of Intratumoral INT230-6 Compared to US Standard of Care in Adults With Soft Tissue Sarcomas (INVINCIBLE-3)
- Conditions
- Interventions
- First Posted Date
- 2024-02-16
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- Intensity Therapeutics, Inc.
- Target Recruit Count
- 333
- Registration Number
- NCT06263231
- Locations
- ๐บ๐ธ
The James Cancer Hospital and Solove Research Institute, Columbus, Ohio, United States
๐จ๐ฆPrincess Margaret Cancer Centre, Toronto, Ontario, Canada
๐ฉ๐ชHelios Klinikum Bad Saarow, Bad Saarow, Germany
NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS)
- First Posted Date
- 2024-02-02
- Last Posted Date
- 2024-04-03
- Lead Sponsor
- St. Jude Children's Research Hospital
- Target Recruit Count
- 139
- Registration Number
- NCT06239272
- Locations
- ๐บ๐ธ
St. Jude Children's Research Hospital, Memphis, Tennessee, United States
OPTI - DOSE: Optimal Dosing of Oral Anticancer Drugs in Older Adults
- Conditions
- Interventions
- First Posted Date
- 2023-07-18
- Last Posted Date
- 2023-11-29
- Lead Sponsor
- University Medical Center Groningen
- Target Recruit Count
- 30
- Registration Number
- NCT05949424
- Locations
- ๐ณ๐ฑ
University Medical Center Groningen, Groningen, Netherlands
Testing Olaparib and Temozolomide Versus the Usual Treatment for Uterine Leiomyosarcoma After Chemotherapy Has Stopped Working
- Conditions
- Interventions
- First Posted Date
- 2022-06-27
- Last Posted Date
- 2024-11-12
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 190
- Registration Number
- NCT05432791
- Locations
- ๐บ๐ธ
Epic Care-Dublin, Dublin, California, United States
๐บ๐ธMarshfield Medical Center - Minocqua, Minocqua, Wisconsin, United States
๐บ๐ธUniversity of Alabama at Birmingham Cancer Center, Birmingham, Alabama, United States
HDM201 and Pazopanib in Patients With P53 Wild-type Advanced/Metastatic Soft Tissue Sarcomas
- Conditions
- Interventions
- First Posted Date
- 2022-01-06
- Last Posted Date
- 2024-04-08
- Lead Sponsor
- Centre Leon Berard
- Target Recruit Count
- 58
- Registration Number
- NCT05180695
- Locations
- ๐ซ๐ท
Institut Bergoniรฉ, Bordeaux, France
๐ซ๐ทInstitut Paoli-Calmettes, Marseille, France
๐ซ๐ทInstitut Claudius Regaud, Toulouse, France
Prospective Translational Study Investigating Possible Molecular prEdictors of Resistance to First-Line pazopanIb
- First Posted Date
- 2020-07-08
- Last Posted Date
- 2020-07-10
- Target Recruit Count
- 25
- Registration Number
- NCT04462445
Implantable Microdevice for the Delivery of Drugs and Their Effect on Tumors in Patients With Metastatic or Recurrent Sarcoma
- Conditions
- Interventions
- First Posted Date
- 2019-12-13
- Last Posted Date
- 2024-10-15
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 20
- Registration Number
- NCT04199026
- Locations
- ๐บ๐ธ
M D Anderson Cancer Center, Houston, Texas, United States
Effects of Pazopanib on Hereditary Hemorrhagic Telangiectasia Related Epistaxis and Anemia (Paz)
- Conditions
- Interventions
- First Posted Date
- 2019-02-22
- Last Posted Date
- 2024-11-06
- Lead Sponsor
- Cure HHT
- Target Recruit Count
- 70
- Registration Number
- NCT03850964
- Locations
- ๐บ๐ธ
Mayo Clinic, Rochester, Minnesota, United States
๐บ๐ธMassachusetts General Hospital, Boston, Massachusetts, United States
๐บ๐ธUniversity of Texas - Southwestern, Dallas, Texas, United States
Pazopanib for the Treatment of Epistaxis in Hereditary Hemorrhagic Telangiectasia
- Conditions
- Interventions
- First Posted Date
- 2019-02-22
- Last Posted Date
- 2022-09-08
- Lead Sponsor
- Cure HHT
- Target Recruit Count
- 30
- Registration Number
- NCT03850730
Combination Chemotherapy With Pazopanib in Children and Adolescents With Relapsed/Refractory Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2018-08-14
- Last Posted Date
- 2018-09-19
- Lead Sponsor
- Samsung Medical Center
- Target Recruit Count
- 46
- Registration Number
- NCT03628131
- Locations
- ๐ฐ๐ท
Samsung Medical Center, Seoul, Korea, Republic of
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.